Key considerations for US biotechs setting up gene therapy studies in the UK and Europe

Cell & Gene Therapy Insights 2023; 9(11), 1369–1373

DOI: 10.18609/cgti.2023.176

Published: 14 November
Chris Moore

"In this Viewpoint, Chris Moore, Clinical Project Manager at drug development consultancy Boyds, explains the key considerations for US biotechs when planning to initiate their gene therapy studies in the UK or Europe, and highlights some of the key regulatory differences."